ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Oncology · Eur J Cancer · 2026-04-12

Secondary analysis of the LAURA RCT in unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy: patient-reported quality of life, functioning and symptoms were not substantially different with osimertinib vs placebo (global QoL deterioration HR 1.14).

Secondary analysis
Arriola et al. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy
Oncology · Lancet · 2026-01-13

Interim analysis of phase 3 RCT (211 Chinese patients, EGFR-mutant MET-amplified NSCLC after EGFR TKI): savolitinib-osimertinib prolonged median PFS vs chemotherapy in TKI-naive (9.8 vs 5.4 months; HR 0.34) and ITT groups; grade ≥3 AEs 57% each.

RCTn = 211
Lu et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.